EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Inhibitory Activity of Red Panda Islet Amyloid Polypeptide on Human IAPP Aggregation

Lauren Phillips iD, Elizabeth L Moffet, Judah Mayfield, Eden L Jonick, Luiza A Nogaj, David A Moffet iD

Journal of Peptide Science · 2026

DOI: 10.1002/psc.70140 ↗

At a glance

Journal article in Journal of Peptide Science, 2026. Written by Lauren Phillips and 5 co-authors. Institution: Department of Chemistry and Biochemistry, Loyola Marymount University, Los Angeles, California, USA. Major MEDLINE topics: Islet Amyloid Polypeptide. 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIDDK NIH HHS, NIH HHS, National Institutes of Health.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Human islet amyloid polypeptide (hIAPP), a 37‐residue hormone co‐secreted with insulin from pancreatic β‐cells, undergoes self‐assembly into cytotoxic amyloid fibrils in the pathogenesis of type 2 diabetes (T2D). The resulting islet amyloid deposits are implicated in progressive β‐cell dysfunction and loss, making hIAPP aggregation an attractive therapeutic target. Nonhuman islet amyloid polypeptide (IAPP) orthologs have recently emerged as a valuable source of mechanistic insight, with several variants—including raccoon and chicken IAPPs—demonstrating the capacity to inhibit hIAPP fibril formation. Here, the biophysical characterization of red panda ( Ailurus fulgens ) IAPP (rpIAPP) and its effects on hIAPP aggregation are reported. Using thioflavin T fluorescence assays, circular dichroism spectroscopy, and atomic force microscopy, red panda IAPP is found to inhibit hIAPP fibrillation at substoichiometric concentrations, with significant inhibitory activity observed at molar ratios as low as 1:0.5 (hIAPP:rpIAPP). These results position red panda IAPP as one of the more potent nonhuman IAPP inhibitors characterized to date and support its further evaluation as a scaffold for the rational design of peptide‐based therapeutics targeting T2D‐associated amyloidogenesis.

Subjects

MeSH terms (MEDLINE)

Islet Amyloid PolypeptideHumansAnimalsAiluridaeProtein AggregatesAmino Acid SequenceMicroscopy, Atomic ForceAmyloid

Author keywords

IAPPamyloid aggregationatomic force microscopycircular dichroisminhibitorislet amyloid polypeptidered pandathioflavin Ttype 2 diabetes

Substances

Islet Amyloid PolypeptideProtein AggregatesAmyloid

Authors and institutions

  • Department of Chemistry and Biochemistry, Loyola Marymount University, Los Angeles, California, USA.
  • Department of Biology, Mount Saint Mary's University, Los Angeles, California, USA.

ORCID profiles: Lauren Phillips, David A Moffet

Funding

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Phillips, L., Moffet, E. L., Mayfield, J., Jonick, E. L., Nogaj, L. A., & Moffet, D. A. (2026). Inhibitory Activity of Red Panda Islet Amyloid Polypeptide on Human IAPP Aggregation. Journal of Peptide Science. https://doi.org/10.1002/psc.70140

Vancouver

Phillips L, Moffet EL, Mayfield J, Jonick EL, Nogaj LA, Moffet DA. Inhibitory Activity of Red Panda Islet Amyloid Polypeptide on Human IAPP Aggregation. Journal of Peptide Science. 2026. doi:10.1002/psc.70140

BibTeX
@article{Phillips2026,
  author = {Phillips, Lauren and Moffet, Elizabeth L and Mayfield, Judah and Jonick, Eden L and Nogaj, Luiza A and Moffet, David A},
  title = {Inhibitory Activity of Red Panda Islet Amyloid Polypeptide on Human IAPP Aggregation},
  journal = {Journal of Peptide Science},
  year = {2026},
  doi = {10.1002/psc.70140}
}
Start for free →